Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Gilead sciences, inc. save search
SK bioscience Appoints New Executives to Accelerate New Growth Strategies
Published: 2023-01-20 (Crawled : 12:20) - prnewswire.com
SNY | News | $48.49 -0.66% -0.66% 1.1M
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: 0.0%
GILD F | $83.7 0.1% 0.1% 4.1M
|
Health Technology
|
| O: -0.7%
H: 0.0%
C: 0.0%
BMRN M | $117.27 0.25% 0.25% 1.2M
|
Health Technology
|
| O: -0.59%
H: 0.0%
C: 0.0%
bioscience growth
Gilead Sciences to Release Fourth Quarter & Full Year 2022 Financial Results on Thursday, February 2, 2023
Published: 2023-01-19 (Crawled : 23:00) - biospace.com/
GILD F | $83.7 0.1% 0.1% 4.1M
|
Health Technology
|
| O: 0.43%
H: 0.0%
C: 0.0%
sciences year financial results
Global Prescription Drugs Market Analysis Report 2022: Increasing Number of Chronic Diseases Worldwide will Continue to Fuel Growth - Forecast to 2027
Published: 2023-01-19 (Crawled : 17:00) - prnewswire.com
TAK | News | $16.03 -0.43% 0.0% 3.7M
|
Health Technology
|
| O: 0.03%
H: 0.0%
C: 0.0%
NVO | $138.09 0.4% 1.38% 1.1M
|
Health Technology
|
| O: 0.14%
H: 0.0%
C: 0.0%
NVS | News 4 d | $89.49 -0.39% 0.01% 1.7M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
JNJ | News 3 d | $168.23 -0.39% -0.04% 6M
|
Health Technology
|
| O: -1.45%
H: 0.0%
C: 0.0%
GSK | News | $35.3 -0.11% 0.14% 3.5M
|
Health Technology
|
| O: 0.23%
H: 0.0%
C: 0.0%
LLY | News | $342.1 -1.7% 0.12% 2.3M
|
Health Technology
|
| O: -1.35%
H: 0.0%
C: 0.0%
BMY | News | $72.45 -0.74% 0.0% 5.4M
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
ABBV | News | $146.28 -0.76% 0.06% 4.6M
|
Health Technology
|
| O: -2.16%
H: 0.0%
C: 0.0%
SNY | News | $48.49 -0.66% -0.66% 1.1M
|
Health Technology
|
| O: -0.92%
H: 0.0%
C: 0.0%
GILD F | $83.7 0.1% 0.1% 4.1M
|
Health Technology
|
| O: 0.43%
H: 0.0%
C: 0.0%
AMGN | News | $253.68 -0.47% -0.47% 2.1M
|
Health Technology
|
| O: -0.9%
H: 0.0%
C: 0.0%
global report growth market
Strata Oncology Announces Addition of Gilead as Strata PATH Trial Collaborator
Published: 2023-01-18 (Crawled : 14:20) - prnewswire.com
GILD F | $83.7 0.1% 0.1% 4.1M
|
Health Technology
|
| O: -0.46%
H: 0.12%
C: -1.51%
trial
Tune Therapeutics Welcomes Noted Industry Leader Dr. John McHutchison to Board of Directors
Published: 2023-01-17 (Crawled : 14:20) - biospace.com/
GILD F | $83.7 0.1% 0.1% 4.1M
|
Health Technology
|
| O: 0.7%
H: 0.37%
C: -0.74%
ASMB | $1.7 1.19% 1.18% 370K
|
Health Technology
|
| O: 7.07%
H: 1.26%
C: -1.26%
therapeutics
Global Antiviral Therapeutics Market 2022 to 2027 - Rising Prevalence of Viral Diseases like HIV and Hepatitis Drives Growth
Published: 2023-01-16 (Crawled : 20:00) - prnewswire.com
PFE | $43.79 -1.04% 0.0% 23M
|
Health Technology
|
| O: -2.74%
H: 0.0%
C: 0.0%
JNJ | News 3 d | $168.23 -0.39% -0.04% 6M
|
Health Technology
|
| O: 0.51%
H: 0.0%
C: 0.0%
BMY | News | $72.45 -0.74% 0.0% 5.4M
|
Health Technology
|
| O: 1.94%
H: 0.52%
C: -1.09%
ABT | News | $109.95 -1.01% 0.0% 4.9M
|
Health Technology
|
| O: 2.05%
H: 0.69%
C: -0.1%
SNY | News | $48.49 -0.66% -0.66% 1.1M
|
Health Technology
|
| O: 1.1%
H: 0.22%
C: 0.02%
GILD F | $83.7 0.1% 0.1% 4.1M
|
Health Technology
|
| O: 0.7%
H: 0.37%
C: -0.74%
hepatitis global antiviral hiv therapeutics growth market
Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies
Published: 2023-01-03 (Crawled : 15:00) - biospace.com/
GILD F | $83.7 0.1% 0.1% 4.1M
|
Health Technology
|
| O: -0.01%
H: 0.0%
C: 0.0%
collaboration therapeutics
Global Precision Cancer Therapeutics Market Report 2022: Overview of Disease Epidemiology, Leading Product sales, Market Estimates and Forecasts, and Competitive Summary of Leading Providers
Published: 2022-12-30 (Crawled : 15:00) - prnewswire.com
PFE | $43.79 -1.04% 0.0% 23M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
NVS | News 4 d | $89.49 -0.39% 0.01% 1.7M
|
Health Technology
|
| O: -0.03%
H: 0.0%
C: 0.0%
JNJ | News 3 d | $168.23 -0.39% -0.04% 6M
|
Health Technology
|
| O: -0.01%
H: 0.0%
C: 0.0%
BMY | News | $72.45 -0.74% 0.0% 5.4M
|
Health Technology
|
| O: 0.13%
H: 0.0%
C: 0.0%
SNY | News | $48.49 -0.66% -0.66% 1.1M
|
Health Technology
|
| O: -0.39%
H: 0.0%
C: 0.0%
GILD F | $83.7 0.1% 0.1% 4.1M
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: 0.0%
EXEL M | $17.48 -1.3% -1.32% 1.6M
|
Health Technology
|
| O: 0.03%
H: 0.0%
C: 0.0%
AZN | $65.54 -0.68% -0.69% 3.1M
|
Health Technology
|
| O: -0.5%
H: 0.0%
C: 0.0%
global disease report therapeutics cancer market
Hagens Berman Sobol Shapiro LLP, Hilliard & Shadowen LLP, and Durie Tangri LLP Announce a Class Action Involving Antiretroviral Drugs
Published: 2022-12-28 (Crawled : 21:00) - prnewswire.com
JNJ | News 3 d | $168.23 -0.39% -0.04% 6M
|
Health Technology
|
| O: -0.26%
H: 0.42%
C: 0.01%
BMY | News | $72.45 -0.74% 0.0% 5.4M
|
Health Technology
|
| O: -0.66%
H: 0.47%
C: -0.28%
GILD F | $83.7 0.1% 0.1% 4.1M
|
Health Technology
|
| O: -0.78%
H: 0.78%
C: 0.41%
Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce Therapeutics
Published: 2022-12-27 (Crawled : 22:00) - globenewswire.com
GILD F | $83.7 0.1% 0.1% 4.1M
|
Health Technology
|
| O: 0.35%
H: 0.0%
C: 0.0%
gs-1811 immunotherapy potential
HIV Clinical Trials Market Research Report by Phase, Study Design, Sponsor, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
Published: 2022-12-26 (Crawled : 13:20) - prnewswire.com
GILD F | $83.7 0.1% 0.1% 4.1M
|
Health Technology
| Email alert
Add to watchlist
NVO | $138.09 0.4% 1.38% 1.1M
|
Health Technology
| Email alert
Add to watchlist
PFE | $43.79 -1.04% 0.0% 23M
|
Health Technology
| Email alert
Add to watchlist
SYNH | $36.09 -0.22% -0.22% 870K
|
Health Services
| Email alert
Add to watchlist
ICLR | $228.26 -1.21% -1.22% 370K
|
Health Technology
| Email alert
Add to watchlist
LLY | News | $342.1 -1.7% 0.12% 2.3M
|
Health Technology
| Email alert
Add to watchlist
covid-19 trials research global report hiv impact study market
Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV
Published: 2022-12-22 (Crawled : 18:00) - biospace.com/
GILD F | $83.7 0.1% 0.1% 4.1M
|
Health Technology
|
| O: -0.2%
H: 0.0%
C: 0.0%
sunlenca treatment fda for hiv approval living
Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer
Published: 2022-12-20 (Crawled : 13:20) - biospace.com/
GILD F | $83.7 0.1% 0.1% 4.1M
|
Health Technology
|
| O: -2.84%
H: 1.93%
C: 1.35%
acquire t-cell therapeutics therapy cancer
Voyager Therapeutics Appoints Grace E. Colón, Ph.D., to its Board of Directors
Published: 2022-12-14 (Crawled : 12:00) - ir.voyagertherapeutics.com
VYGR S | $9.005 0.17% 0.17% 250K
|
Health Technology
|
| O: -2.35%
H: 1.76%
C: -6.41%
PGEN | News 0 d | $1.64 1.23% 1.22% 4.3M
|
Health Technology
|
| O: 0.9%
H: 2.98%
C: 1.79%
GILD F | $83.7 0.1% 0.1% 4.1M
|
Health Technology
|
| O: -1.7%
H: 0.0%
C: 0.0%
CDNA F | $15.28 0.53% 0.52% 440K
|
Health Technology
|
| O: -5.83%
H: 4.12%
C: 1.9%
therapeutics
Three-Year Follow-Up Analysis of Kite’s Yescarta® CAR T-cell Therapy (ZUMA-5 Trial) - 52% of Patients With Indolent Lymphomas Continued to Have Ongoing Responses at a Median Follow-Up of 40.5 Months
Published: 2022-12-12 (Crawled : 19:00) - biospace.com/
GILD F | $83.7 0.1% 0.1% 4.1M
|
Health Technology
|
| O: -1.34%
H: 0.81%
C: 0.79%
yescarta ongoing lymphomas t-cell therapy
Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
Published: 2022-12-09 (Crawled : 16:00) - biospace.com/
ACLX | $34.0 2.6% 2.53% 370K
|
|
| O: 30.25%
H: 0.0%
C: 0.0%
GILD F | $83.7 0.1% 0.1% 4.1M
|
Health Technology
|
| O: 1.66%
H: 0.0%
C: 0.0%
collaboration
Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma
Published: 2022-12-09 (Crawled : 14:00) - biospace.com/
ACLX | $34.0 2.6% 2.53% 370K
|
|
| O: 30.25%
H: 0.0%
C: 0.0%
GILD F | $83.7 0.1% 0.1% 4.1M
|
Health Technology
|
| O: 1.66%
H: 0.0%
C: 0.0%
collaboration
ImmunoGen Announces Clinical Collaboration with Gilead to Evaluate Pivekimab Sunirine in Combination with Magrolimab in Relapsed/Refractory Acute Myeloid Leukemia
Published: 2022-12-09 (Crawled : 13:00) - biospace.com/
IMGN | $4.745 0.74% 0.74% 1.7M
|
Health Technology
|
| O: -0.39%
H: 0.0%
C: 0.0%
GILD F | $83.7 0.1% 0.1% 4.1M
|
Health Technology
|
| O: 1.66%
H: 0.0%
C: 0.0%
collaboration leukemia acute myeloid leukemia
Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model Myriad Genetics, Inc., a leader in genetic testing and preci...
Published: 2022-12-09 (Crawled : 13:00) - biospace.com/
SXT | $72.54 -0.82% 0.0% 75K
|
Distribution Services
|
| O: 1.04%
H: 0.0%
C: 0.0%
PFE | $43.79 -1.04% 0.0% 23M
|
Health Technology
|
| O: 3.66%
H: 0.0%
C: 0.0%
TRIB | $1.085 -5.65% -5.99% 47K
|
Health Technology
|
| O: -7.03%
H: 0.0%
C: 0.0%
REPL | $25.89 -0.92% -0.93% 350K
|
Health Technology
|
| O: 5.04%
H: 0.0%
C: 0.0%
MYGN | $20.38 2.88% 2.8% 320K
|
Health Technology
|
| O: 0.15%
H: 0.0%
C: 0.0%
IMGN | $4.745 0.74% 0.74% 1.7M
|
Health Technology
|
| O: -0.39%
H: 0.0%
C: 0.0%
GILD F | $83.7 0.1% 0.1% 4.1M
|
Health Technology
|
| O: 1.66%
H: 0.0%
C: 0.0%
BNTX | $143.69 0.81% 0.8% 440K
|
Health Technology
|
| O: 4.9%
H: 0.0%
C: 0.0%
risk breast genetic cancer study
Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO - IO) Annual Congress
Published: 2022-12-08 (Crawled : 13:00) - globenewswire.com
JNCE | $1.19 5.31% 5.04% 510K
|
Health Technology
|
| O: 1.82%
H: 1.52%
C: -7.91%
GILD F | $83.7 0.1% 0.1% 4.1M
|
Health Technology
|
| O: -0.51%
H: 0.0%
C: 0.0%
medical trial therapeutics
Gainers vs Losers
| 66% | 34% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.